The anaplastic lymphoma kinase (ALK) gene fusion accounts for about 3%–6% of NSCLC, which is the second most commonly identified targeted driver gene after epidermal growth factor receptor (EGFR) mutations in NSCLC (Yu et al., 2016). This evidence concerns the gene ALK and non-small cell lung carcinoma.